ACXP News and Press, Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update PR Newswire STATEN ISLAND, N.Y. , Feb. 16, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Comp...

USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors PR Newswire STATEN ISLAND, N.Y. , Feb. 2, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class...

Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals PR Newswire The objective of this new phase of collaboration with Leiden University Medical Center (LUMC) is to further advance the rece...

2025-11-12 10:11:33 ET Acurx Pharmaceuticals, Inc. (ACXP) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST... Read the full article on Seeking Alpha For further details see: Acurx Pharmaceuticals, Inc. (ACXP) Q3 2025 Earnings Call Transcript

2025-11-12 07:10:16 ET More on Acurx Pharmaceuticals Seeking Alpha’s Quant Rating on Acurx Pharmaceuticals Historical earnings data for Acurx Pharmaceuticals Financial information for Acurx Pharmaceuticals Read the full article on Seeking Alpha ...

Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update PR Newswire STATEN ISLAND, N.Y. , Nov. 12, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a ne...

RWE AG ADR (RWEOY) is expected to report $0.16 for Q3 2025 Hillenbrand Inc (HI) is expected to report $0.62 for Q4 2025 Ardent Health Inc. (ARDT) is expected to report $0.42 for Q3 2025 Quince Therapeutics Inc. (QNCX) is expected to report $-0.2 for Q3 2025 GlobalFoundries Inc. (G...

Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens PR Newswire DNA polymerase (pol) IIIC inhibitors are an innovative new class of antibiotics, the first in more than 30 years...

Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference PR Newswire Pioneering data demonstrate that Acurx's U.S. and EU Phase 3-ready DNA pol IIIC in...

Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update PR Newswire STATEN ISLAND, N.Y. , Oct. 27, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late...